Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Fi

Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patients
Oakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX:

Related Keywords

United States , Israel , America , Dennis Mcnamara , Trevor Burns , Heart Failure Research , Company Phase , University Of Pittsburgh Medical Center , Company Annual Information Form , Cardiol Therapeutics Inc , Nasdaq , Newsfile Corp , University Of Pittsburgh , Pittsburgh Medical Center , North America , Latin America , Drug Designation , Orphan Drug Designation , Cardiol Therapeutics , Annual Information Form , Investor Relations , Cardiol , Herapeutics , Nnounces , First , Patient , Unrolled , Archer , Hase , Linical , Trial , Ardiolrx , Treatment , Cute , Myocarditis ,